Week in Review: WuXi PharmaTech and PRA Form Clinical CRO JV

WuXi PharmaTech is forming a JV with PRA, a US-based clinical-stage CRO, that will offer Phase I-IV clinical trial services in China; ShangPharma agreed to a go-private offer from its Founder and TPG group that values the CRO at $173 million; Guangzhou Techpool Bio-Pharma in-licensed the China rights to Bondronat, an oncology drug from Roche; AstraZeneca will collaborate with Fudan University to discover the mechanism behind a TCM product used to treat cardiovascular problems; and Omega Diagnostics, a Scottish test-maker, won approval from the SFDA to market its food allergy test in China. More details…. Stock Symbols: (NYSE: WX) (NYSE: SHP) (VS: ROG) (NYSE: AZN) Share this with colleagues: // //